Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-β therapy

Hepatology

Volumn 25, Issue 3, 1997, Pages 750-753

  Kurosaki, Masayuki ^a   Enomoto, Nobuyuki ^a   Murakami, Takeshi ^a   Sakuma, Ikuo ^a   Asahina, Yasuhiro ^a   Yamamoto, Chikara ^a   Ikeda, Takaaki ^c   Tozuka, Shinichi ^c   Izumi, Namiki ^d   Marumo, Fumiaki ^a   Sato, Chifumi ^b  

^a Tokyo Medical and Dental University   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c YOKOSUKA KYOSAI HOSPITAL   (Japan)

^d MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMINO ACID; BETA INTERFERON; VIRUS PROTEIN; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS GENE; VIRUS TYPING;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; RNA, VIRAL;

EID: 0031042869     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250343     Document Type: Article

References (11)

1. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. HEPATOLOGY 1990;12:671-675.
2. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
3. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Tada M, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-915.
4. Takano S, Satomura Y, Omata M, The Japan Acute Hepatitis Cooperative Study Group. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Gastroenterology 1994; 107:805-811.
5. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. HEPATOLOGY 1993;18:1319-1325.
6. Platanias LC, Uddin S, Colamonici OR. Tyrosine phosphorylation of the α and β subunits of the type I interferon receptor. J Biol Chem 1994;269: 17761-17764.
7. Pellegrini S, John J, Shearer M, Kerr IM, Stark GR. Use of a selective marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol 1989;9:4605-4612.
8. Colamonici OR, Pfeffer LM. Structure of the human Interferon receptor. Pharmacol Ther 1991;52:227-233.
9. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. HEPATOLOGY 1995;22:700-706.
10. Garson JA, Brillanti S, Whitby K, Foli M, Deaville R, Masci C, Miglioli M, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995;45:348-353.
11. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42: 299-305.